Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible Meeting Abstract


Authors: Petrylak, D. P.; Flaig, T. W.; Mar, N.; Gourdin, T. S.; Srinivas, S.; Rosenberg, J. E.; Guseva, M.; Yu, Y.; Narayanan, S.; Hoimes, C. J.
Abstract Title: Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible
Meeting Title: 2022 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 40
Issue: 16 Suppl.
Meeting Dates: 2022 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2022-06-01
Language: English
ACCESSION: WOS:000863680301402
PROVIDER: wos
DOI: 10.1200/JCO.2022.40.16_suppl.4582
Notes: Meeting Abstract: 4582 -- Meeting also held virtually -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Yao Yu
    115 Yu